Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
HOME > TOP STORIES
TOP STORIES
-
REGULATORY Japan Approves Pluvicto, Izervay, and Lots More; Subcutaneous Rybrevant Not on Roster
September 22, 2025
-
ORGANIZATION JPMA Sets Up Multilateral Advocacy Group to Bolster Global Voice: International Affairs Chair
September 19, 2025
-
REGULATORY FPMAJ Urges Blanket Drug Price Hikes to Offset Inflation: FY2026 Reform Talks
September 18, 2025
-
REGULATORY J&J’s Subcutaneous Rybrevant Faces Delay in Japan Approval Process
September 17, 2025
-
BUSINESS Alnylam Sees Japan Business Doubling as Amvuttra Expands into ATTR-CM
September 17, 2025
-
BUSINESS Predictability Key to Novartis’ Japan Investment, Says International Chief
September 16, 2025
-
BUSINESS LEO Pharma Reinforces Japan Push toward Dermatology Leadership
September 12, 2025
-
BUSINESS Sawai and T’s Pharma Won Forxiga Generics by Skirting Patent, Will the Strategy Hold?
September 11, 2025
-
REGULATORY Reblozyl Faces Price Cut after Cost-Effectiveness Assessment
September 11, 2025
-
BUSINESS Teijin Pharma Bets on Ascendis Rare Disease Assets as Feburic Sales Crumble
September 10, 2025
-
BUSINESS Amicus CEO Confident on US$1 Billion Sales Target as Japan Pompe Launch Gets Underway
September 9, 2025
-
BUSINESS KM Biologics Developing Higher-Yield Liquid Immunoglobulin to Boost Efficiency and Supply
September 8, 2025
-
ORGANIZATION JPMA Code & Compliance Chair Stresses Need to Embed Spirit of Revised COP
September 8, 2025
-
COMMENTARY MHLW Grows Jittery over Supply Risks amid Rising Foreign Investments
September 8, 2025
-
BUSINESS And Pharma Chief Pledges Growth Strategy as New Generics Holding Firm Takes Shape
September 5, 2025
-
ORGANIZATION JPMA ICH Project Chair Sees RWE as Potential Complement to Clinical Trials
September 5, 2025
-
BUSINESS Bayer Pushes Cross-Border Open Innovation with New Co.Lab Connect Program
September 4, 2025
-
ORGANIZATION JPMA Regulatory Chief Seeks Balanced Approach on Japanese PI Waivers
September 3, 2025
-
REGULATORY Pharma Groups Press Pricing Reform at First Public-Private WG Meeting
September 2, 2025
-
REGULATORY Japan Panel Clears Izervay, Nexletol for Approval; Eylea Biosimilars Edge Ahead Too
September 1, 2025
ページ
As Japan approaches the Fiscal System Council’s “autumn recommendation,” a notable shift is taking shape. The Ministry of Finance (MOF),…
Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…